Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lupin Limited ( (IN:LUPIN) ) has shared an announcement.
Lupin Limited announced that the U.S. FDA conducted an inspection at its manufacturing facility in Goa, India, resulting in a Form-483 with seven observations. The company is committed to addressing these observations and maintaining compliance with CGMP standards, which is crucial for its operational integrity and market reputation.
More about Lupin Limited
Lupin Limited operates in the pharmaceutical industry, focusing on the development, production, and marketing of a wide range of generic and branded formulations and active pharmaceutical ingredients. The company is a significant player in the global pharmaceutical market, with a strong emphasis on compliance and quality standards.
Average Trading Volume: 22,008
Technical Sentiment Signal: Strong Buy
Current Market Cap: 925B INR
See more insights into LUPIN stock on TipRanks’ Stock Analysis page.